Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2012

01-12-2012 | Original Article

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study

Authors: Daniela Di Giuda, Giovanni Camardese, Anna Rita Bentivoglio, Fabrizio Cocciolillo, Arianna Guidubaldi, Lorella Pucci, Isabella Bruno, Luigi Janiri, Alessandro Giordano, Alfonso Fasano

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2012

Login to get access

Abstract

Purpose

Psychiatric symptoms frequently occur in patients with movement disorders. They are not a mere reaction to chronic disability, but most likely due to a combination of psychosocial factors and biochemical dysfunction underlying the movement disorder. We assessed dopamine transporter (DAT) availability by means of 123I-FP-CIT SPECT, and motor and psychiatric features in patients with Parkinson’s disease, primary dystonia and essential tremor, exploring the association between SPECT findings and symptom severity.

Methods

Enrolled in the study were 21 patients with Parkinson’s disease, 14 patients with primary dystonia and 15 patients with essential tremor. The severity of depression symptoms was assessed using the Hamilton depression rating scale, anxiety levels using the Hamilton anxiety rating scale and hedonic tone impairment using the Snaith-Hamilton pleasure scale. Specific 123I-FP-CIT binding in the caudate and putamen was calculated based on ROI analysis. The control group included 17 healthy subjects.

Results

As expected, DAT availability was significantly decreased in patients with Parkinson’s disease, whereas in essential tremor and dystonia patients it did not differ from that observed in the control group. In Parkinson’s disease patients, an inverse correlation between severity of depression symptoms and DAT availability in the left caudate was found (r = −0.63, p = 0.002). In essential tremor patients, levels of anxiety symptoms were inversely correlated with DAT availability in the left caudate (r = −0.69, p = 0.004). In dystonia patients, the severities of both anxiety and depression symptoms were inversely associated with DAT availability in the left putamen (r = −0.71, p = 0.004, and r = −0.75, p = 0.002, respectively). There were no correlations between psychometric scores and 123I-FP-CIT uptake ratios in healthy subjects.

Conclusion

We found association between presynaptic dopaminergic function and affective symptoms in different movement disorders. Interestingly, the inverse correlation was present in each group of patients, supporting the fascinating perspective that common subcortical substrates may be involved in both anxiety and depression dimensions and movement disorders.
Literature
1.
go back to reference Miller KM, Okun MS, Fernandez HF, Jacobson CE, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson’s disease, dystonia, and essential tremor. Mov Disord. 2007;22(5):666–72.PubMedCrossRef Miller KM, Okun MS, Fernandez HF, Jacobson CE, Rodriguez RL, Bowers D. Depression symptoms in movement disorders: comparing Parkinson’s disease, dystonia, and essential tremor. Mov Disord. 2007;22(5):666–72.PubMedCrossRef
2.
go back to reference Nuti A, Ceravolo R, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, et al. Psychiatric comorbidity in a population of Parkinson’s disease patients. Eur J Neurol. 2004;11(5):315–20.PubMedCrossRef Nuti A, Ceravolo R, Piccinni A, Dell’Agnello G, Bellini G, Gambaccini G, et al. Psychiatric comorbidity in a population of Parkinson’s disease patients. Eur J Neurol. 2004;11(5):315–20.PubMedCrossRef
3.
go back to reference Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatr. 2005;13(10):844–51. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatr. 2005;13(10):844–51.
4.
go back to reference Dissanayaka NN, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–45.PubMedCrossRef Dissanayaka NN, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–45.PubMedCrossRef
5.
go back to reference Tan EK, Fook-Chong S, Lum SY, Gabriel C, Koh KK, Prakash KM, et al. Non-motor manifestations in essential tremor: use of a validated instrument to evaluate a wide spectrum of symptoms. Parkinsonism Relat Disord. 2005;11(6):375–80.PubMedCrossRef Tan EK, Fook-Chong S, Lum SY, Gabriel C, Koh KK, Prakash KM, et al. Non-motor manifestations in essential tremor: use of a validated instrument to evaluate a wide spectrum of symptoms. Parkinsonism Relat Disord. 2005;11(6):375–80.PubMedCrossRef
6.
go back to reference Chatterjee A, Jurewicz EC, Applegate LM, Louis ED. Personality in essential tremor: further evidence of non-motor manifestations of the disease. J Neurol Neurosurg Psychiatry. 2004;75(7):958–61.PubMedCrossRef Chatterjee A, Jurewicz EC, Applegate LM, Louis ED. Personality in essential tremor: further evidence of non-motor manifestations of the disease. J Neurol Neurosurg Psychiatry. 2004;75(7):958–61.PubMedCrossRef
7.
go back to reference Lencer R, Steinlechner S, Stahlberg J, Rehling H, Orth M, Baeumer T, et al. Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatr. 2009;80(10):1176–9.PubMedCrossRef Lencer R, Steinlechner S, Stahlberg J, Rehling H, Orth M, Baeumer T, et al. Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatr. 2009;80(10):1176–9.PubMedCrossRef
8.
go back to reference Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C, et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010;25(4):459–65.PubMedCrossRef Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C, et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010;25(4):459–65.PubMedCrossRef
10.
go back to reference Flinn D, Bazzell W. Psychiatric aspects of abnormal movement disorders. Brain Res Bull. 1983;11(2):153–61.PubMedCrossRef Flinn D, Bazzell W. Psychiatric aspects of abnormal movement disorders. Brain Res Bull. 1983;11(2):153–61.PubMedCrossRef
11.
12.
go back to reference Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology. 1984;34(5):642–6.PubMedCrossRef Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology. 1984;34(5):642–6.PubMedCrossRef
13.
go back to reference Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(Pt 6):1314–22.PubMedCrossRef Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(Pt 6):1314–22.PubMedCrossRef
14.
go back to reference Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res. 2009;204(1):32–66.PubMedCrossRef Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res. 2009;204(1):32–66.PubMedCrossRef
15.
go back to reference Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(4):565–80.PubMedCrossRef Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(4):565–80.PubMedCrossRef
16.
go back to reference Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24(3):149–50.PubMedCrossRef Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24(3):149–50.PubMedCrossRef
17.
go back to reference Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46(2):227–32.PubMed Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46(2):227–32.PubMed
18.
go back to reference Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23(11):1580–7.PubMedCrossRef Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23(11):1580–7.PubMedCrossRef
19.
go back to reference Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 2001;158(2):314–6.PubMedCrossRef Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 2001;158(2):314–6.PubMedCrossRef
20.
go back to reference Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatr Res. 2006;147(2–3):243–8. Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatr Res. 2006;147(2–3):243–8.
21.
go back to reference Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry. 2003;160(10):1836–41.PubMedCrossRef Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry. 2003;160(10):1836–41.PubMedCrossRef
22.
go back to reference Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005;89(1–3):115–23.PubMedCrossRef Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005;89(1–3):115–23.PubMedCrossRef
23.
go back to reference Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, et al. Greater availability of dopamine transporters in patients with major depression – a dual-isotope SPECT study. Psychiatr Res. 2008;162(3):230–5.CrossRef Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, et al. Greater availability of dopamine transporters in patients with major depression – a dual-isotope SPECT study. Psychiatr Res. 2008;162(3):230–5.CrossRef
24.
go back to reference Wu H, Lou C, Huang Z, Shi G. SPECT imaging of dopamine transporters with 99mTc-TRODAT-1 in major depression and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2011;23(1):63–7.PubMedCrossRef Wu H, Lou C, Huang Z, Shi G. SPECT imaging of dopamine transporters with 99mTc-TRODAT-1 in major depression and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2011;23(1):63–7.PubMedCrossRef
25.
go back to reference Louis ED, Benito-Leon J, Bermejo-Pareja F. Self-reported depression and anti-depressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. Eur J Neurol. 2007;14(10):1138–46.PubMedCrossRef Louis ED, Benito-Leon J, Bermejo-Pareja F. Self-reported depression and anti-depressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. Eur J Neurol. 2007;14(10):1138–46.PubMedCrossRef
26.
go back to reference Li ZW, Xie MJ, Tian DS, Li JJ, Zhang JP, Jiao L, et al. Characteristics of depressive symptoms in essential tremor. J Clin Neurosci. 2011;18(1):52–6.PubMedCrossRef Li ZW, Xie MJ, Tian DS, Li JJ, Zhang JP, Jiao L, et al. Characteristics of depressive symptoms in essential tremor. J Clin Neurosci. 2011;18(1):52–6.PubMedCrossRef
27.
go back to reference Chandran V, Pal PK, Reddy JY, Thennarasu K, Yadav R, Shivashankar N. Non-motor features in essential tremor. Acta Neurol Scand. 2012;125(5):332–7.PubMedCrossRef Chandran V, Pal PK, Reddy JY, Thennarasu K, Yadav R, Shivashankar N. Non-motor features in essential tremor. Acta Neurol Scand. 2012;125(5):332–7.PubMedCrossRef
28.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
29.
go back to reference Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.PubMedCrossRef Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.PubMedCrossRef
30.
go back to reference Fahn S, Elton R, Committee MotUD. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson’s Disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153–163.p. 293–304. Fahn S, Elton R, Committee MotUD. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson’s Disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153–163.p. 293–304.
31.
go back to reference Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13 Suppl 3:2–23.PubMed Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13 Suppl 3:2–23.PubMed
32.
go back to reference Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433–44.PubMedCrossRef Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433–44.PubMedCrossRef
33.
go back to reference Burke RE, Fahn S. Serum trihexyphenidyl levels in the treatment of torsion dystonia. Neurology. 1985;35(7):1066–9.PubMedCrossRef Burke RE, Fahn S. Serum trihexyphenidyl levels in the treatment of torsion dystonia. Neurology. 1985;35(7):1066–9.PubMedCrossRef
34.
go back to reference Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443–50.PubMedCrossRef Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443–50.PubMedCrossRef
35.
go back to reference Kretschmann H, Weinrich W. Cranial neuroimaging and clinical neuroanatomy. Stuttgart: Thieme; 1992. Kretschmann H, Weinrich W. Cranial neuroimaging and clinical neuroanatomy. Stuttgart: Thieme; 1992.
36.
go back to reference Newberg A, Amsterdam J, Shults J. Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun. 2007;28(1):3–6.PubMedCrossRef Newberg A, Amsterdam J, Shults J. Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun. 2007;28(1):3–6.PubMedCrossRef
37.
38.
go back to reference Mellers JD, Quinn NP, Ron MA. Psychotic and depressive symptoms in Parkinson’s disease. A study of the growth hormone response to apomorphine. Br J Psychiatry. 1995;167(4):522–6.PubMedCrossRef Mellers JD, Quinn NP, Ron MA. Psychotic and depressive symptoms in Parkinson’s disease. A study of the growth hormone response to apomorphine. Br J Psychiatry. 1995;167(4):522–6.PubMedCrossRef
39.
go back to reference Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatr. 2000;15(7):644–9.CrossRef Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatr. 2000;15(7):644–9.CrossRef
40.
41.
go back to reference Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.PubMedCrossRef Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.PubMedCrossRef
42.
go back to reference McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther. 2006;28(11):1882–91.PubMedCrossRef McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther. 2006;28(11):1882–91.PubMedCrossRef
43.
go back to reference Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale. Br J Psychiatry. 1995;167(1):99–103.PubMedCrossRef Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale. Br J Psychiatry. 1995;167(1):99–103.PubMedCrossRef
44.
go back to reference Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–14.PubMedCrossRef Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–14.PubMedCrossRef
45.
go back to reference Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214–20.PubMedCrossRef Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214–20.PubMedCrossRef
46.
go back to reference Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2006;18(3):397–401.PubMedCrossRef Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2006;18(3):397–401.PubMedCrossRef
47.
go back to reference Rickards H. Depression in neurological disorders: an update. Curr Opin Psychiatr. 2006;19(3):294–8.CrossRef Rickards H. Depression in neurological disorders: an update. Curr Opin Psychiatr. 2006;19(3):294–8.CrossRef
48.
go back to reference Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5–12.PubMedCrossRef Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5–12.PubMedCrossRef
49.
go back to reference Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):392–6.PubMedCrossRef Maron E, Kuikka JT, Ulst K, Tiihonen J, Vasar V, Shlik J. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):392–6.PubMedCrossRef
50.
go back to reference van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med. 2008;49(5):757–63.PubMedCrossRef van der Wee NJ, van Veen JF, Stevens H, van Vliet IM, van Rijk PP, Westenberg HG. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med. 2008;49(5):757–63.PubMedCrossRef
51.
go back to reference Schneier FR, Abi-Dargham A, Martinez D, Slifstein M, Hwang DR, Liebowitz MR, et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety. 2009;26(5):411–8.PubMedCrossRef Schneier FR, Abi-Dargham A, Martinez D, Slifstein M, Hwang DR, Liebowitz MR, et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety. 2009;26(5):411–8.PubMedCrossRef
52.
go back to reference Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000;15(4):669–77.PubMedCrossRef Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000;15(4):669–77.PubMedCrossRef
53.
go back to reference Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: implications for the symptomatic threshold. Neurology. 1997;48(6):1578–83.PubMedCrossRef Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: implications for the symptomatic threshold. Neurology. 1997;48(6):1578–83.PubMedCrossRef
54.
go back to reference Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601–7.PubMedCrossRef Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601–7.PubMedCrossRef
55.
go back to reference Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108–15.PubMedCrossRef Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108–15.PubMedCrossRef
56.
go back to reference Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25(10):3132–6.PubMedCrossRef Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25(10):3132–6.PubMedCrossRef
57.
go back to reference Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.PubMedCrossRef Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.PubMedCrossRef
58.
go back to reference Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, et al. Personality traits and brain dopaminergic function in Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98(23):13272–7.PubMedCrossRef Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, et al. Personality traits and brain dopaminergic function in Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98(23):13272–7.PubMedCrossRef
59.
go back to reference Moriyama TS, Felicio AC, Chagas MH, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310(1–2):53–7.PubMedCrossRef Moriyama TS, Felicio AC, Chagas MH, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310(1–2):53–7.PubMedCrossRef
60.
go back to reference Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lepine JP, et al. Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord. 2010;25(2):157–66.PubMedCrossRef Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lepine JP, et al. Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord. 2010;25(2):157–66.PubMedCrossRef
61.
go back to reference Louis ED. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. Lancet Neurol. 2010;9(6):613–22.PubMedCrossRef Louis ED. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. Lancet Neurol. 2010;9(6):613–22.PubMedCrossRef
62.
go back to reference Hoshi E, Tremblay L, Feger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci. 2005;8(11):1491–3.PubMedCrossRef Hoshi E, Tremblay L, Feger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci. 2005;8(11):1491–3.PubMedCrossRef
63.
go back to reference Boyer P. Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatr Scand Suppl. 2000;406:24–9.PubMedCrossRef Boyer P. Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatr Scand Suppl. 2000;406:24–9.PubMedCrossRef
64.
go back to reference Floresco SB, St Onge JR, Ghods-Sharifi S, Winstanley CA. Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making. Cognit Affect Behav Neurosci. 2008;8(4):375–89.CrossRef Floresco SB, St Onge JR, Ghods-Sharifi S, Winstanley CA. Cortico-limbic-striatal circuits subserving different forms of cost-benefit decision making. Cognit Affect Behav Neurosci. 2008;8(4):375–89.CrossRef
65.
go back to reference Isaias IU, Canesi M, Benti R, Gerundini P, Cilia R, Pezzoli G, et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun. 2008;29(4):349–53.PubMedCrossRef Isaias IU, Canesi M, Benti R, Gerundini P, Cilia R, Pezzoli G, et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun. 2008;29(4):349–53.PubMedCrossRef
66.
go back to reference Schwartz M, Groshar D, Inzelberg R, Hocherman S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(6):385–9.PubMedCrossRef Schwartz M, Groshar D, Inzelberg R, Hocherman S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(6):385–9.PubMedCrossRef
67.
go back to reference Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17(2):843–50.PubMed Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17(2):843–50.PubMed
68.
go back to reference Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology. 2009;72(24):2097–103.PubMedCrossRef Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology. 2009;72(24):2097–103.PubMedCrossRef
69.
go back to reference Sareen J, Campbell DW, Leslie WD, Malisza KL, Stein MB, Paulus MP, et al. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol Psychiatry. 2007;61(3):396–404.PubMedCrossRef Sareen J, Campbell DW, Leslie WD, Malisza KL, Stein MB, Paulus MP, et al. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol Psychiatry. 2007;61(3):396–404.PubMedCrossRef
70.
go back to reference Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719–35.PubMedCrossRef Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719–35.PubMedCrossRef
71.
go back to reference Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327–37.PubMedCrossRef Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327–37.PubMedCrossRef
72.
go back to reference Fleminger S. Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychol Med. 1991;21(3):629–38.PubMedCrossRef Fleminger S. Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychol Med. 1991;21(3):629–38.PubMedCrossRef
73.
go back to reference Cubo E, Martin PM, Martin-Gonzalez JA, Rodriguez-Blazquez C, Kulisevsky J. Motor laterality asymmetry and nonmotor symptoms in Parkinson’s disease. Mov Disord. 2010;25(1):70–5.PubMedCrossRef Cubo E, Martin PM, Martin-Gonzalez JA, Rodriguez-Blazquez C, Kulisevsky J. Motor laterality asymmetry and nonmotor symptoms in Parkinson’s disease. Mov Disord. 2010;25(1):70–5.PubMedCrossRef
74.
75.
go back to reference Lorenzetti V, Allen NB, Whittle S, Yucel M. Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. J Affect Disord. 2010;120(1–3):112–9.PubMedCrossRef Lorenzetti V, Allen NB, Whittle S, Yucel M. Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. J Affect Disord. 2010;120(1–3):112–9.PubMedCrossRef
76.
go back to reference Menza MA, Mark MH, Burn DJ, Brooks DJ. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(2):176–9.PubMed Menza MA, Mark MH, Burn DJ, Brooks DJ. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1995;7(2):176–9.PubMed
77.
go back to reference Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(Pt 4):859–76.PubMedCrossRef Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(Pt 4):859–76.PubMedCrossRef
78.
go back to reference Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci. 1987;10:197–245.CrossRef Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci. 1987;10:197–245.CrossRef
79.
go back to reference Baxter Jr LR, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry. 1985;42(5):441–7.PubMedCrossRef Baxter Jr LR, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry. 1985;42(5):441–7.PubMedCrossRef
80.
go back to reference Buchsbaum MS, Wu J, DeLisi LE, Holcomb H, Kessler R, Johnson J, et al. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord. 1986;10(2):137–52.PubMedCrossRef Buchsbaum MS, Wu J, DeLisi LE, Holcomb H, Kessler R, Johnson J, et al. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord. 1986;10(2):137–52.PubMedCrossRef
81.
go back to reference Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl. 1998;(35):26–37. Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl. 1998;(35):26–37.
82.
go back to reference Hansen ES, Hasselbalch S, Law I, Bolwig TG. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol. 2002;5(1):1–10.PubMedCrossRef Hansen ES, Hasselbalch S, Law I, Bolwig TG. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol. 2002;5(1):1–10.PubMedCrossRef
83.
go back to reference van den Heuvel OA, Veltman DJ, Groenewegen HJ, Witter MP, Merkelbach J, Cath DC, et al. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry. 2005;62(8):922–33.PubMedCrossRef van den Heuvel OA, Veltman DJ, Groenewegen HJ, Witter MP, Merkelbach J, Cath DC, et al. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry. 2005;62(8):922–33.PubMedCrossRef
84.
go back to reference Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48(3):359–66.PubMed Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48(3):359–66.PubMed
85.
go back to reference Cortes R, Soriano E, Pazos A, Probst A, Palacios JM. Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27(2):473–96.PubMedCrossRef Cortes R, Soriano E, Pazos A, Probst A, Palacios JM. Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience. 1988;27(2):473–96.PubMedCrossRef
86.
go back to reference Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51(12):1885–91.PubMedCrossRef Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51(12):1885–91.PubMedCrossRef
87.
go back to reference Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23(12):1776–80.PubMedCrossRef Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23(12):1776–80.PubMedCrossRef
88.
go back to reference Tatsch K, Poepperl G. Quantitative approach to dopaminergic brain imaging. Q J Nucl Med Mol Imaging. 2012;56:27–38.PubMed Tatsch K, Poepperl G. Quantitative approach to dopaminergic brain imaging. Q J Nucl Med Mol Imaging. 2012;56:27–38.PubMed
89.
go back to reference Amsterdam JD, Newberg AB. A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology. 2007;55(3–4):167–70.PubMedCrossRef Amsterdam JD, Newberg AB. A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology. 2007;55(3–4):167–70.PubMedCrossRef
Metadata
Title
Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study
Authors
Daniela Di Giuda
Giovanni Camardese
Anna Rita Bentivoglio
Fabrizio Cocciolillo
Arianna Guidubaldi
Lorella Pucci
Isabella Bruno
Luigi Janiri
Alessandro Giordano
Alfonso Fasano
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2232-7

Other articles of this Issue 12/2012

European Journal of Nuclear Medicine and Molecular Imaging 12/2012 Go to the issue